Subclonal TP53 and KRAS variants combined with poor treatment response identify ultra-high-risk pediatric T-ALL patients.
Kempter T, Richter-Pechanska P, Michel K, Rausch T, Erarslan Uysal B, Eckert C, Zimmermann M, Stanulla M, Schrappe M, Cario G, Köhrer S, Attarbaschi A, Korbel JO, Kunz JB, Kulozik A.
Kempter T, et al. Among authors: zimmermann m.
Blood Adv. 2025 Jan 14:bloodadvances.2024014209. doi: 10.1182/bloodadvances.2024014209. Online ahead of print.
Blood Adv. 2025.
PMID: 39808796